Uta Dirksen, SIOPE President and Acting Director of Pediatrics III at the University of Duisburg-Essen, shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
“Inotuzumab ozogamicin is highly active as a reinduction and bridge to HSCT in children with high risk first B-cell acute lymphoblastic leukaemia relapse.
Happy to share the article. Grateful for the chance to participate in this game changing trial.
Novel therapies can turn the page in pediatric cancers.
We need equal access to novel therapies for all children with cancer.
We need more clinical trials in Europe.”
Title: Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial
Authors: Nicolò Peccatori, Franco Locatelli, Anneke Ammerlaan, Yilin Jiang, Vincent van der Velden, Andrej Lissat, Anna Nilsson, Bella Bielorai, Barbara De Moerloose, Susana Rives, Alba Rubio-San Simon, Uta Dirksen, Gernot Engstler, Benedicte Bruno, Cristina Diaz-de-Heredia, Benoit Brethon, Francisco Bautista Sirvent, Fanny Rialland, Lucie Sramkova, Marlène Pasquet, Karsten Nysom, Nicoletta Bertorello, Peter Bader, Jochen Buechner, Inge van der Sluis, Berna Beverloo, Barbara Sleight, Arend von Stackelberg, Christian Zwaan, Erica Brivio
Read the Full Article on The Lancet Haematology
More posts featuring Uta Dirksen.